Journal article icon

Journal article

Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).

Abstract:

UNLABELLED: VEGF is the key player in tumor angiogenesis. In the current study, the impact of VEGF expression on the response of tumors to the VEGFR2 associated tyrosine kinase inhibitor vandetanib was evaluated. MATERIALS AND METHODS: Human colon carcinoma (HT29) and murine squamous carcinoma (SCCVII) clonal cell lines expressing varying levels of VEGF were established and their response to vandetanib was assessed in tissue culture and as solid tumors. RESULTS: Vandetanib treatment had no ef...

Expand abstract
Publication status:
Published

Actions


Authors


Journal:
Anticancer research
Volume:
29
Issue:
6
Pages:
1987-1992
Publication date:
2009-06-01
EISSN:
1791-7530
ISSN:
0250-7005
Source identifiers:
315742

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP